Mitiglinide
As of the edition of 20 October 2026, Mitiglinide is a small molecule: marketed, first approved in 2011 (JP); acts on ABCC8 and KCNJ11.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Glubes
- First approved
- 22 April 2011 (JP)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Kissei Pharmaceutical
- Registered trials
- 9, 0 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Digestive system; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 5 | 4 | 0 | 0 |
| All trials | 9 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Kissei Pharmaceutical | Applicant | 2011 to now |